Literature DB >> 11841844

Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin.

Andrew J H Gearing1, Susan J Thorpe, Karen Miller, Matthew Mangan, Paul G Varley, Tim Dudgeon, George Ward, Christina Turner, Robin Thorpe.   

Abstract

We have shown that two of the matrix metalloproteinases (MMPs), matrilysin and stromelysin-1, are capable of cleaving all of the human IgG subclasses. The cleavage occurs at a conserved site in the CH(2) domain of the heavy chain of IgG, releasing a single chain Fc-like fragment. We have not been able to demonstrate cleavage of IgA, IgD, IgM or IgE classes, which lack the cleavage site, nor could we show cleavage of IgG by collagenase, gelatinase, macrophage metalloelastase or membrane-type (MT)-MMP. This cleavage of IgG, by separating the antigen-binding (Fabprime prime or minute)(2) from the Fc portion, will remove much of the immunoglobulins' functionality, e.g. complement fixation, Fc receptor binding. In the context of a tumour producing matrilysin or stromelysin, this may represent a way in which the tumour protects itself from ADCC. In inflamed or damaged tissues where plasma protein leakage occurs, degradation by MMPs may be a mechanism for clearance of IgG.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841844     DOI: 10.1016/s0165-2478(01)00333-9

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  19 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

3.  Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence.

Authors:  Fang Wu; Suraj G Bhansali; Wing Cheung Law; Earl J Bergey; Paras N Prasad; Marilyn E Morris
Journal:  Pharm Res       Date:  2012-02-29       Impact factor: 4.200

4.  Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice.

Authors:  Fang Wu; Mitalee Tamhane; Marilyn E Morris
Journal:  AAPS J       Date:  2012-03-06       Impact factor: 4.009

5.  The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge.

Authors:  Randall J Brezski; Allison Oberholtzer; Brandy Strake; Robert E Jordan
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 6.  Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?

Authors:  Randall J Brezski; Robert E Jordan
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

7.  Resistance to Trastuzumab in Breast Cancer.

Authors:  Paula R Pohlmann; Ingrid A Mayer; Ray Mernaugh
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  Fragmentation of a recombinant monoclonal antibody at various pH.

Authors:  Georgeen Gaza-Bulseco; Hongcheng Liu
Journal:  Pharm Res       Date:  2008-05-13       Impact factor: 4.200

9.  Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge.

Authors:  Randall J Brezski; Omid Vafa; Diane Petrone; Susan H Tam; Gordon Powers; Mary H Ryan; Jennifer L Luongo; Allison Oberholtzer; David M Knight; Robert E Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-07       Impact factor: 11.205

10.  Engineered protease-resistant antibodies with selectable cell-killing functions.

Authors:  Michelle Kinder; Allison R Greenplate; Katharine D Grugan; Keri L Soring; Katharine A Heeringa; Stephen G McCarthy; Gregory Bannish; Meredith Perpetua; Frank Lynch; Robert E Jordan; William R Strohl; Randall J Brezski
Journal:  J Biol Chem       Date:  2013-08-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.